Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

FDA's OTC OFFICE DIRECTOR-CANDIDATE MICHAEL WEINTRAUB, MD, is reportedly among the frontrunners being considered by the agency for the new post. The 51-year-old clinical pharmacologist is currently an associate professor of community medicine, and pharmacology and medicine at the University of Rochester. FDA sent out requests to medical societies in late March for nominations for director of the new Office of OTC Products ("The Pink Sheet" April 8, p. 4). The Nonprescription Drug Manufacturers Association has submitted suggestions for the function of the OTC office at the request of FDA. Weintraub is a noted pharmacologist with little Washington experience, having spent the last 20 years at the University of Rochester. During that time he was an associate of Louis Lasagna, MD, before Lasagna left to become dean of Tufts University's Sackler School of Graduate Biomedical Sciences. Weintraub is also a long-time acquaintance of Center for Drug Evaluation and Research Director Carl Peck, MD. While at Rochester, Weintraub has published two studies in the OTC area, one on taste comparisons between cough syrups and a phenylpropanolamine efficacy study for weight reduction. The study, entitled "Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification," was published in a 1986 issue of Clinical Pharmacology and Therapeutics. Acutrim is marketed by Ciba Consumer. Prior to his tenure at Rochester, Weintraub was trained in internal medicine at the University of California at Los Angeles. He received his MD and bachelor's degree from the University of Pennsylvania.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts